Antioxidants & Redox Signaling (ARS) is the leading journal dedicated to the understanding of redox principles governing health and disease. This Journal provides and explores key aspects of the important and expanding world of redox-based therapeutics—genetic, pharmacological, and nutritional. Cutting-edge research focuses on structural biology, stem cells, regenerative medicine, epigenetics, imaging, clinical outcomes, and preventive and therapeutic nutrition, among other areas.ARS has expanded to create two unique foci within one journal: ARS Discoveries and ARS Therapeutics. ARS Discoveries (24 issues) publishes the highest-caliber breakthroughs in basic and applied research. ARS Therapeutics (12 issues) is the first publication of its kind that will help enhance the entire field of redox biology by showcasing the potential of redox sciences to change health outcomes.ARS coverage includes:ROS/RNS as messengersGaseous signal transducersHypoxia and tissue oxygenationmicroRNAProkaryotic systemsLessons from plant biologyARS is under the editorial leadership of Editor-in-Chief Chandan K. Sen, PhD, The Ohio State University Wexner Medical Center, and other leading investigators. View the entire editorial board.Audience: Cell biologists, molecular biologists, biochemists, medical researchers, and nutritionists, among others.ARS provides "Instant Online" publication 72 hours after acceptance. Average time to first decision: 18 days Average time to triage decision: 48 hoursIndexed/Abstracted in:MEDLINE; PubMed; PubMed Central; Current Contents?/Life Sciences; Science Citation Index Expanded;Science Citation Index?; Biochemistry & Biophysics Citation Index?; Biological Abstracts; BIOSIS Previews;Journal Citation Reports/Science Edition; EMBASE/Excerpta Medica; EMBiology; Scopus; Chemical Abstracts;ProQuest databases

抗氧化劑和氧化還原信號(ARS)是致力于了解氧化還原原理控制健康和疾病的領(lǐng)先雜志。這本雜志提供和探索了氧化還原療法的重要和不斷擴(kuò)大的世界的關(guān)鍵方面-遺傳，藥理和營養(yǎng)。前沿研究領(lǐng)域包括結(jié)構(gòu)生物學(xué)、干細(xì)胞、再生醫(yī)學(xué)、表觀遺傳學(xué)、影像學(xué)、臨床結(jié)果、預(yù)防和治療營養(yǎng)等。ARS已經(jīng)擴(kuò)展到在一本雜志中創(chuàng)建兩個(gè)獨(dú)特的焦點(diǎn):ARS發(fā)現(xiàn)和ARS治療。ARS的發(fā)現(xiàn)(24期)出版了基礎(chǔ)研究和應(yīng)用研究的最高水平的突破。ARS Therapeutics(12期)是第一本此類出版物，通過展示氧化還原科學(xué)改變健康結(jié)果的潛力，將有助于增強(qiáng)氧化還原生物學(xué)的整個(gè)領(lǐng)域。ARS覆蓋范圍包括:ROS / RNS信使氣體傳感器的信號缺氧和組織氧合微原核系統(tǒng)植物生物學(xué)課程ARS由主編Chandan K. Sen博士、俄亥俄州立大學(xué)Wexner醫(yī)學(xué)中心和其他主要研究人員領(lǐng)導(dǎo)。查看整個(gè)編輯委員會。聽眾:細(xì)胞生物學(xué)家，分子生物學(xué)家，生物化學(xué)家，醫(yī)學(xué)研究人員，營養(yǎng)學(xué)家等等。ARS在驗(yàn)收后72小時(shí)內(nèi)提供“即時(shí)在線”出版物。第一次決定的平均時(shí)間:18天平均分類時(shí)間:48小時(shí)索引/抽象:MEDLINE;PubMed;公共醫(yī)學(xué)中心;當(dāng)前內(nèi)容?/生命科學(xué);科學(xué)引文索引擴(kuò)展;生物化學(xué)與生物物理學(xué)引文索引;生物提取;生物預(yù)覽;期刊引用報(bào)告/科學(xué)版;EMBASE /摘要》;EMBiology;斯高帕斯;化學(xué)文摘;ProQuest數(shù)據(jù)庫